PSORS13
MCID: PSR018
MIFTS: 40

Psoriasis 13 (PSORS13)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 13

MalaCards integrated aliases for Psoriasis 13:

Name: Psoriasis 13 57 12 74
Psoriasis Susceptibility 13 57 29 13 6
Psors13 57 12 74
Psoriasis Vulgaris 74 72
Psoriasis 74 72
Psoriasis, Susceptibility to, Type 13 40
Psoriasis 13, Susceptibility to 57
Pv 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0111287
MeSH 44 D011565
MedGen 42 C3279754
UMLS 72 C0033860 C0263361

Summaries for Psoriasis 13

UniProtKB/Swiss-Prot : 74 Psoriasis 13: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis 13, also known as psoriasis susceptibility 13, is related to guttate psoriasis and pustular psoriasis, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 13 is TRAF3IP2 (TRAF3 Interacting Protein 2). The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

Disease Ontology : 12 A psoriasis that has material basis in variation in TRAF3IP2 on chromosome 6q21.

More information from OMIM: 614070 PS177900

Related Diseases for Psoriasis 13

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 13 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1246)
# Related Disease Score Top Affiliating Genes
1 guttate psoriasis 12.7
2 pustular psoriasis 12.7
3 psoriasis 15, pustular 12.6
4 psoriasis 4 12.6
5 psoriasis 3 12.6
6 psoriasis 10 12.6
7 psoriasis 6 12.5
8 psoriasis 5 12.5
9 psoriasis 12 12.5
10 psoriasis 8 12.5
11 psoriatic arthritis 12.5
12 psoriasis 9 12.5
13 psoriasis 15 12.5
14 polycythemia vera 12.4
15 mental retardation and psoriasis 12.3
16 pustulosis palmaris et plantaris 12.3
17 tranebjaerg svejgaard syndrome 12.1
18 psoriatic juvenile idiopathic arthritis 11.9
19 psoriasis 1 11.9
20 impetigo herpetiformis 11.8
21 juvenile rheumatoid arthritis 11.6
22 geographic tongue 11.6
23 pemphigus 11.5
24 parapsoriasis 11.5
25 pemphigus vulgaris, familial 11.5
26 arthritis 11.5
27 persistent vegetative state 11.5
28 pulmonary valve stenosis 11.5
29 spondyloarthropathy 1 11.5
30 vitiligo-associated multiple autoimmune disease susceptibility 1 11.5
31 psoriasis 14, pustular 11.5
32 subacute cutaneous lupus erythematosus 11.4
33 chronic recurrent multifocal osteomyelitis 11.4
34 temporomandibular ankylosis 11.4
35 singleton-merten syndrome 1 11.2
36 systemic onset juvenile idiopathic arthritis 11.2
37 variegate porphyria 11.2
38 psoriasis 2 11.2
39 psoriasis 7 11.2
40 psoriasis 11 11.2
41 skin disease 11.2
42 nail disorder, nonsyndromic congenital, 1 11.1
43 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.1
44 singleton-merten syndrome 2 11.1
45 primary cutaneous amyloidosis 11.1
46 combined immunodeficiency with skin granulomas 11.1
47 singleton-merten syndrome 11.1
48 dermatitis 10.9
49 dermatitis, atopic 10.9
50 autoimmune disease 10.8

Graphical network of the top 20 diseases related to Psoriasis 13:



Diseases related to Psoriasis 13

Symptoms & Phenotypes for Psoriasis 13

Clinical features from OMIM:

614070

UMLS symptoms related to Psoriasis 13:


pruritus, exanthema, psoriasiform rash

Drugs & Therapeutics for Psoriasis 13

Drugs for Psoriasis 13 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 466)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
carbamide peroxide Approved Phase 4 124-43-6
8
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
9
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5282493 5311052
10
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
11
Sodium citrate Approved, Investigational Phase 4 68-04-2
12 Orange Approved Phase 4
13 Strawberry Approved Phase 4
14 Artichoke Approved Phase 4
15
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
16
Tofacitinib Approved, Investigational Phase 4 477600-75-2
17
Adalimumab Approved Phase 4 331731-18-1 16219006
18
Zinc Approved, Investigational Phase 4 7440-66-6 32051
19
Desoximetasone Approved Phase 4 382-67-2 5311067
20
Certolizumab pegol Approved Phase 4 428863-50-7
21
Mercaptopurine Approved Phase 4 50-44-2 667490
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
24
tannic acid Approved Phase 4 1401-55-4
25
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
26 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
27
Metformin Approved Phase 4 657-24-9 4091 14219
28
Ustekinumab Approved, Investigational Phase 4 815610-63-0
29 Vedolizumab Approved Phase 4 943609-66-3
30
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
31
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
32
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
33
Capsaicin Approved Phase 4 404-86-4 1548943
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
37
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
38
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
39 Retinol palmitate Phase 4
40 retinol Phase 4
41 Antiparasitic Agents Phase 4
42 Antiprotozoal Agents Phase 4
43 Antimalarials Phase 4
44 Hydrocortisone 17-butyrate 21-propionate Phase 4
45 Hydrocortisone hemisuccinate Phase 4
46 Hydrocortisone-17-butyrate Phase 4
47 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
48 Omega 3 Fatty Acid Phase 4
49 Chelating Agents Phase 4
50 Tin Fluorides Phase 4

Interventional clinical trials:

(show top 50) (show all 1555)
# Name Status NCT ID Phase Drugs
1 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
2 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
3 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
5 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
6 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
7 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
8 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
9 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
10 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
11 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
14 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
15 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
16 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
17 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
18 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
19 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
20 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
21 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
22 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
23 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
24 A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Completed NCT01761019 Phase 4 Taclonex Topical Suspension
25 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
26 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
27 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
28 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
29 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
30 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
31 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
32 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
33 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
34 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
35 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
36 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
37 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
38 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
39 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
40 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
41 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
42 An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
43 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
44 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
45 A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis Completed NCT02274792 Phase 4 Etanercept
46 A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS Completed NCT02187172 Phase 4 Ustekinumab;Placebo
47 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
48 A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
49 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast Completed NCT02749370 Phase 4 Etanercept
50 Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis Completed NCT01766440 Phase 4 Calcitriol 3 mcg/g ointment

Search NIH Clinical Center for Psoriasis 13

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis 13

Genetic tests related to Psoriasis 13:

# Genetic test Affiliating Genes
1 Psoriasis Susceptibility 13 29 TRAF3IP2

Anatomical Context for Psoriasis 13

MalaCards organs/tissues related to Psoriasis 13:

41
Skin, Testes, T Cells, Endothelial, Liver, Bone, Monocytes

Publications for Psoriasis 13

Articles related to Psoriasis 13:

(show all 17)
# Title Authors PMID Year
1
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. 8 71
20953186 2010
2
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. 8 71
20953188 2010
3
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. 71
24120361 2013
4
CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis. 71
22581863 2012
5
[Pruritus in Germany-a Google search engine analysis]. 38
29876613 2019
6
Juvenile psoriasis: an epidemiological study of 69 cases. 38
27374182 2018
7
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. 38
30214261 2018
8
Remission of psoriasis 13 years after autologous stem cell transplant. 38
26125223 2015
9
Increased subclinical atherosclerosis in patients with chronic plaque psoriasis. 38
25463081 2014
10
Severely photosensitive psoriasis: a phenotypically defined patient subset. 38
19536141 2009
11
[The anti-tubercular drugs in the treatment of psoriasis]. 38
19801725 2009
12
An exploratory population-based case-control study of primary biliary cirrhosis. 38
10796879 2000
13
Narrowband UVB phototherapy for psoriasis: results with fixed increments by skin type (as opposed to percentage increments). 38
10321520 1999
14
The chemotactic activity of T-lymphocytes in response to interleukin 8 is significantly decreased in patients with psoriasis and atopic dermatitis. 38
9028795 1996
15
[Psoriasis: development and fatal complications]. 38
2048897 1991
16
[Comparative study between 120 mg. of anapsos and a placebo in 37 psoriasis patients]. 38
6759814 1982
17
Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. 38
781848 1976

Variations for Psoriasis 13

ClinVar genetic disease variations for Psoriasis 13:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TRAF3IP2 NM_147686.4(TRAF3IP2): c.28G> A (p.Asp10Asn) single nucleotide variant Benign rs33980500 6:111913262-111913262 6:111592059-111592059

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 13:

74
# Symbol AA change Variation ID SNP ID
1 TRAF3IP2 p.Asp19Asn VAR_047349 rs33980500

Expression for Psoriasis 13

Search GEO for disease gene expression data for Psoriasis 13.

Pathways for Psoriasis 13

GO Terms for Psoriasis 13

Sources for Psoriasis 13

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....